4.6 Article

MicroPNA-205-5p targets the HOXD9-Snail1 axis to inhibit triple negative breast cancer cell proliferation and chemoresistance

期刊

AGING-US
卷 13, 期 3, 页码 3945-3956

出版社

IMPACT JOURNALS LLC
DOI: 10.18632/aging.202363

关键词

microRNA; breast cancer; chemotherapy resistance; EMT

资金

  1. Fujian Medical Minimally Invasive Center (Breast Surgery) [08011]

向作者/读者索取更多资源

Our study investigated the biological role of miR-205 in breast cancer, demonstrating that its overexpression could inhibit cell proliferation and chemoresistance by targeting the HOXD9-Snail1 axis. This research provides novel insight for therapeutic strategies of breast cancer through targeting miR-205/HOXD9/Snail1.
MicroRNA-205 (miR-205) is believed to be related to the progress of tumors. HOXD9 has been proved to be expressed abnormally in several kinds of cancers. However, the role of miR-205 and HOXD9 in breast cancer remains unclear. The biological role of miR-205 in breast cancer cell proliferation and chemoresistance was investigated. The expression of miR-205 in clinical tissues and breast cancer cell lines were analyzed using quantitative real-time PCR test (qRT-PCR); Overexpression and knockdown modes of miR-205 were established to study cell proliferation and chemotherapy -resistant. Moreover, the potential relationships between miR-205 and HOXD9/Snail1 were measured using qRT-PCR, western blot, and chemotherapy-resistant study. miR-205 was lowly expressed in breast cancer tissues and cell lines: Overexpression of miR-205 could inhibit cell proliferation and chemotherapy-resistance. Moreover, we proved that rniR-205 could target the HOXD9-Snail1 axis to suppress triple negative breast cancer cell proliferation and chemoresistance. The activation of Snail1 gene by HOXD9 was also proved in this study. The present study may provide a novel insight for the therapeutic strategies of breast cancer through targeting miR-205/HOXD9/Snail1.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据